Recombinant phenotyping of cytomegalovirus sequence variants detected after 200 or 100 days of valganciclovir prophylaxis

Transplantation

Volumn 90, Issue 12, 2010, Pages 1409-1413

  Chou, Sunwen ^a,b   Marousek, Gail ^b   Boivin, Guy ^c   Goyette, Nathalie ^c   Farhan, Mahdi ^d   Ives, Jane A L ^d   Elston, Robert ^d  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

^c LAVAL UNIVERSITY   (Canada)

^d ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

Cytomegalovirus; Prophylaxis; Resistance; Transplant; Valganciclovir

Indexed keywords

DNA POLYMERASE; PLACEBO; VALGANCICLOVIR;

AMINO ACID SUBSTITUTION; ARTICLE; CASE REPORT; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG SENSITIVITY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GRAFT RECIPIENT; HUMAN; KIDNEY TRANSPLANTATION; NONHUMAN; PHASE 3 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SEQUENCE ANALYSIS; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS MUTATION; VIRUS STRAIN; VIRUS VIABILITY;

ANTIVIRAL AGENTS; BASE SEQUENCE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FOLLOW-UP STUDIES; GANCICLOVIR; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; TIME FACTORS;

EID: 78650812043     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181fdd9d2     Document Type: Article

References (16)

1. Eid AJ, Razonable RR. New developments in the management of cytomegalovirus infection after solid organ transplantation. Drugs 2010; 70: 965.
2. KDIGO Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9(suppl 3): S1.
3. Kotton CN, Kumar D, Caliendo AM, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 89: 779.
4. Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4: 611.
5. Eid AJ, Arthurs SK, Deziel PJ, et al. Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: Therapeutic implications and outcomes. Clin Transplant 2008; 22: 162.
6. Humar A, Lebranchu Y, Vincenti F, et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010; 10: 1228.
7. Palmer SM, Limaye AP, Banks M, et al. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: A randomized, controlled trial. Ann Intern Med 2010; 152: 761.
8. Jabs DA, Martin BK, Forman MS, et al. Mutations conferring ganciclovir resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. J Infect Dis 2001; 183: 333.
9. Boivin G, Goyette N, Gilbert C, et al. Clinical impact of ganciclovirresistant cytomegalovirus infections in solid organ transplant patients. Transpl Infect Dis 2005;7: 166.
10. Lurain NS, Chou S. Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev 2010; 23: 689-712.
11. Boivin G, Goyette N, Rollag H, et al. Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir. Antivir Ther 2009; 14: 697.
12. Elston R, Boivin G, Goyette N, et al. Genotypic analysis of cytomegalovirus UL54 and UL97 genes derived from patients receiving 100 or 200 days of valganciclovir prophylaxis [abstract 1202]. Presented at the American Transplant Congress, San Diego, CA, May 1-5, 2010.
13. Cihlar T, FullerMD,Cherrington JM. Characterization of drug resistanceassociated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. J Virol 1998; 72: 5927.
14. Chou S. Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance. Antimicrob Agents Chemother 2010; 54: 2371.
15. Drew WL. Ganciclovir resistance: A matter of time and titre. Lancet 2000; 356: 609.
16. Boutolleau D, Deback C, Bressollette-Bodin C, et al. Resistance pattern of cytomegalovirus (CMV) after oral valganciclovir therapy in transplant recipients at high-risk for CMV infection. Antiviral Res 2009; 81: 174.